SAVA Q4 2021 Earnings — Cassava Sciences, Inc. Revenue & Financial Results | Market Cap Arena

SAVACassava Sciences, Inc.

$116M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$10M

Operating Income

-$14M

Net Income

-$14M

EPS (Diluted)

$-0.35

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$522,000

Balance Sheet

Total Assets

$267M

Total Liabilities

$13M

Stockholders' Equity

$254M

Cash & Equivalents

$233M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$10M	-$2M	-580.8%
Operating Income	-$14M	-$3M	-450.5%
Net Income	-$14M	-$3M	-441.3%